These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 12409654)

  • 1. Thalidomide and immunomodulatory drugs as cancer therapy.
    Raje N; Anderson KC
    Curr Opin Oncol; 2002 Nov; 14(6):635-40. PubMed ID: 12409654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.
    Vallet S; Witzens-Harig M; Jaeger D; Podar K
    Expert Opin Pharmacother; 2012 Mar; 13(4):473-94. PubMed ID: 22324734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunomodulatory drugs.
    Crane E; List A
    Cancer Invest; 2005; 23(7):625-34. PubMed ID: 16305990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.
    Schafer PH
    Expert Opin Pharmacother; 2012 Jul; 13(10):1541-2. PubMed ID: 22646699
    [No Abstract]   [Full Text] [Related]  

  • 5. The thalidomide saga.
    Melchert M; List A
    Int J Biochem Cell Biol; 2007; 39(7-8):1489-99. PubMed ID: 17369076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Thalidomide: mechanisms of action and new insights in hematology].
    Leleu X; Micol JB; Guieze R; Berthon C; Kuhnovsky F; Terriou L; Moreau AS; Yakoub-Agha I; Bauters F; Facon T
    Rev Med Interne; 2005 Feb; 26(2):119-27. PubMed ID: 15710258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [IMiDs in hematology].
    Wémeau M; Gauthier J; Leleu X; Yakoub-Agha I
    Bull Cancer; 2011 Aug; 98(8):879-87. PubMed ID: 21827980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide: the emerging role of a novel targeted agent in malignancies.
    Kalmadi S; Baz R; Mahindra A
    Drugs Today (Barc); 2007 Feb; 43(2):85-95. PubMed ID: 17353946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma.
    Richardson P; Anderson K
    J Clin Oncol; 2004 Aug; 22(16):3212-4. PubMed ID: 15249587
    [No Abstract]   [Full Text] [Related]  

  • 10. Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide.
    Bartlett JB; Tozer A; Stirling D; Zeldis JB
    Br J Cancer; 2005 Sep; 93(6):613-9. PubMed ID: 16222306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thalidomide analogs as emerging anti-cancer drugs.
    Dredge K; Dalgleish AG; Marriott JB
    Anticancer Drugs; 2003 Jun; 14(5):331-5. PubMed ID: 12782937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IMiDs: a novel class of immunomodulators.
    Knight R
    Semin Oncol; 2005 Aug; 32(4 Suppl 5):S24-30. PubMed ID: 16085014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomodulatory analogues of thalidomide in the treatment of multiple myeloma.
    Suppiah R; Srkalovic JG; Hussein MA
    Clin Lymphoma Myeloma; 2006 Jan; 6(4):301-5. PubMed ID: 16507207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thalidomide derived immunomodulatory drugs (IMiDs) as potential therapeutic agents.
    Marriott JB; Dredge K; Dalgleish AG
    Curr Drug Targets Immune Endocr Metabol Disord; 2003 Sep; 3(3):181-6. PubMed ID: 12871024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thalidomide in multiple myeloma--clinical trials and aspects of drug metabolism and toxicity.
    Breitkreutz I; Anderson KC
    Expert Opin Drug Metab Toxicol; 2008 Jul; 4(7):973-85. PubMed ID: 18624684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The promise of thalidomide: evolving indications.
    Joglekar S; Levin M
    Drugs Today (Barc); 2004 Mar; 40(3):197-204. PubMed ID: 15148528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thalidomide in cancer medicine.
    Eleutherakis-Papaiakovou V; Bamias A; Dimopoulos MA
    Ann Oncol; 2004 Aug; 15(8):1151-60. PubMed ID: 15277253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological effects of thalidomide and its chemical and functional analogs.
    Dredge K; Marriott JB; Dalgleish AG
    Crit Rev Immunol; 2002; 22(5-6):425-37. PubMed ID: 12803319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma.
    Raje N; Hideshima T; Anderson KC
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1239-47. PubMed ID: 17020458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome.
    Maier SK; Hammond JM
    Ann Pharmacother; 2006 Feb; 40(2):286-9. PubMed ID: 16403850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.